Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

Table 4 Incremental total costs of caspofungin and micafungin compared with anidulafungin for each variation of input parameter in a one-way sensitivity analysis

Parameter	Basecase	Change in input lower than base case			Change in input higher than base case
		Input	Incremental costs versus anidulafungin^a		Input	Incremental costs versus anidulafungin^a
		Input	Caspofungin	Micafungin	Input	Caspofungin	Micafungin
Anidulafungin drug-acquisition costs (£)	£300 per vial	−20 %	1252	1068	+20 %	126	−59
Mortality	[19]	Assumed equivalent	535	287	NA	NA	NA
Clinical success and mortality	[19]	Assumed equivalent	316	47	NA	NA	NA
Clinical success, survive, ICU LOS (days)	11.5	7	1446	1544	14	263	−80
Clinical success, die, ICU LOS (days)	12.8	7	−166	−705	14	868	757
Clinical failure, survive, ICU LOS (days)	19.0	10	968	949	30	349	−37
Clinical failure, die, ICU LOS (days)	20.3	10	151	−241	30	1194	1205
ICU cost per day (£)	1528	1000	544	318	2000	819	672
Time to clinical failure (treatment switch) (days)	3	1	654	482	5	724	527
Clinical failure and die, time to death (days)	7	3	717	543	10	668	475
Clinical success, IV treatment duration (days)	10	7	536	415	14	892	624

ICU intensive care unit; IV intravenous; LOS length of stay; NA not available
^aPositive costs indicate that the total cost of the comparator regimen is more expensive than anidulafungin; negative costs indicate that the comparator regimen is less expensive than anidulafungin

ISSN: 1471-2334